HTB

Antiretrovirals

Cabotegravir-LA submitted to EMA for use as PrEP in Europe

AIDS 2022: Efficacy of DTG- vs EFV-based first-line ART in advanced HIV with CD4 <50 cells/mm3

Islatravir update: treatment studies to use a lower dose but PrEP research discontinued in favour of MK-8537

Low levels of RPV-LA might explain failure with injectable ART despite perfect adherence

Lenacapavir approved in the EU and UK to treat multidrug resistant HIV

Dolutegravir-based ART in children and adolescents: effective in six African countries

Early data on injecting CAB/RPV-LA into thigh muscle

Simplifed lenacapavir dosing: PK results in HIV negative study

Lenacapavir gets positive opinion for approval in the EU to treat MDR HIV

Combination bNAb’s sustain viral suppression for 40 weeks: phase 1 results

Lenacapavir in MDR HIV: phase 3 results of CAPELLA study published

ViiV licenses long-acting cabotegravir (CAB-LA) for generic access

CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART

FDA approves dispersible dolutegravir/abacavir/3TC for children

Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits

CROI 2022: Islatravir studies for HIV treatment and PrEP

US FDA removes need for oral lead-in with long-acting cabotegravir/rilpivirine injections: indication expanded to adolescents

CROI 2022: Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies

CROI 2022: Injectable CAB/RPV-LA results after three years follow-up

CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study

CROI 2022: Lenacapavir in treatment-experienced participants, and as PrEP in macaques

US FDA approves 2-monthly dosing option for long-acting injectable cabotegravir/rilpivirine

Gilead to pay $1.25 billion plus royalties to ViiV Healthcare for bictegravir infringing on dolutegravir patent

Selected islatravir studies stop enrolment: further complications with important investigational drugs

FDA further limit use of islatravir in ongoing studies

Lenacapavir: drug resistance after viral rebound in treatment experienced participants

Implications of historical M184V on use of dual dolutegravir/lamivudine ART

Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks

Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study

NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales

MSD/Merck stop once-weekly NNRTI MK-8507: islatravir studies continue with closer monitoring

NHS Scotland approves long-acting cabotegravir and rilpivirine injections

Lenacapavir submitted to EMA for MDR HIV

Pipeline report 2021: HIV drugs in development

IAS 2021: lenacapavir studies show impressive results in naive, extensive drug resistance and potential as PrEP

IAS 2021: HIV pipeline drugs: CAB/RPV LA, fostemsavir, paediatric dolutegravir, lenacapavir, islatravir, MK-8507 and albuvirtide

Lenacapavir submitted to FDA as long-acting treatment for MDR HIV

CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP

Gilead and Merck/MSD to collaborate on long-acting HIV combination of lenacapavir and islatravir

CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance

CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021

US FDA approves long-acting injectable HIV treatment: monthly dosing

Long-acting injectable HIV treatment approved in the EU: includes two-monthly dosing

Fostemsavir approved in the EU (Rukobia): NICE deferred in the UK

EU approves dolutegravir 5 mg dispersible for children older than four weeks

New formulation of dolutegravir will make modern ART available for babies and young children at less than $120 a year

New neonatal liquid formulations of dolutegravir have comparable bioavailability to dispersible paediatric tablet

EMA issues positive opinion to approve cabotegravir LA/rilpivirine LA injections (Vocabria/Rekambys) as new HIV treatment

Capsid inhibitor lenacapavir, dosed six-monthly, has high barrier to drug resistance and no cross-resistance to other classes

Single doses of MK-8507 reduce viral load by mean –1.5 log and support once-weekly dosing above 80 mg

Capsid inhibitor lenacapavir (GS-6207) allows for 6-monthly dosing

US FDA approves dolutegravir/lamivudine (Dovato) as switch option

EMA extends indication for darunavir/r to include adolescents >12 years

ViiV resubmits cabotegravir plus rilpivirine long-acting injections (Cabenuva, Vocabria) to FDA for approval

ADVANCE 96-week results: dolutegravir weight gain continues, especially in women and when used with TAF – no evidence of a plateau

FDA approves fostemsavir (Rukobia) for multidrug resistant HIV in the US

FDA approves dolutegravir formulations to treat infants and young children

Fit for purpose: antiretroviral treatment optimisation March 2020

Long-acting cabotegravir and rilpivirine injections support two-monthly dosing

Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing

First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance

Long-acting cabotegravir and rilpivirine: similar results in women and men 

FDA decision on long-acting cabotegravir/rilpivirine (Cabenuva, Vocabria) injections delayed due to scale-up manufacturing problems

Fostemsavir submitted to EMA for treating multidrug resistant HIV

Gilead announces licensing agreement for Rockefeller University bNAbs

Post navigation